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Abstract
The candidate H5N1 vaccine virus NIBRG-14 was created in response to a call from the World Health Organisation in 2004 to
prepare candidate vaccine viruses (CVVs) to combat the threat of an H5N1 pandemic. NIBRG-14 was created by reverse
genetics and is composed of the neuraminidase (NA) and modified haemagglutinin (HA) genes from A/Vietnam/1194/2004
and the internal genes of PR8, a high growing laboratory adapted influenza A(H1N1) strain. Due to time constraints, the
non-coding regions (NCRs) of A/Vietnam/1194/2004 HA were not determined prior to creating NIBRG-14. Consequently, the
sequence of the primers used to clone the modified A/Vietnam/1194/2004 HA was based upon previous experience of
cloning H5N1 viruses. We report here that the HA 39 NCR sequence of NIBRG-14 is different to that of the parental wild type
virus A/Vietnam/1194/2004; however this does not appear to impact on its growth or antigen yield. We introduced
additional small changes into the 39NCR of NIBRG-14; these had only minor effects on viral growth and antigen content.
These findings may serve to assure the influenza vaccine community that generation of CVVs using best-guess NCR
sequences, based on sequence alignments, are likely to produce robust viruses.
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Introduction
Influenza A viruses have a single-stranded negative sense RNA
genome composed of eight individual RNA segments. Each
segment is comprised of one or more open reading frames (ORFs)
flanked by non-coding regions (NCRs) at their 39 and 59 ends. The
39 and 59 NCRs of influenza A viruses are important for virus
replication [1–3] with the terminal 12 or 13 nucleotides of the 39
and 59 NCRs, respectively, being highly conserved among the
eight RNA segments and different influenza A virus strains [1,4–
6]. Beyond these conserved nucleotides the sequences of the NCRs
are segment specific with variable levels of conservation amongst
different viruses. Sequencing the ends of RNA molecules is
technically demanding; 59 end sequences can be determined by
direct sequencing of the RNA using reverse transcriptase whilst the
39 ends require more sophisticated approaches such as the ‘RNA
ligation’ method [7–9]. Thus, with the bulk of influenza virus
sequencing focussing on the internal coding regions, the NCRs are
largely ignored except by those researchers specifically interested
in them. Also, when sequence information is available in the public
domain for the NCRs, information regarding their derivation is
often unavailable. It is therefore frequently not possible to regard
the NCR sequences as genuine as it is not known whether the
sequences have been determined de novo or represent the sequence
of primers used during PCR and/or cloning.
The lack of influenza NCR sequences in the public domain and
the lack of information regarding the provenance of published
NCR sequences is a problem when they are required for primer
design for specific genome segment amplification of novel viruses.
Consequently, primers may often be designed based upon
incorrect or incomplete information. This is a concern when
novel candidate influenza vaccine viruses (CVVs) need to be
developed rapidly, for example at the onset of an influenza
pandemic.
The CVV NIBRG-14 was developed in 2004 at the National
Institute for Biological Standards and Control (NIBSC) [10]
following an urgent call from the World Health Organisation
(WHO) to generate CVVs derived from highly pathogenic avian
H5N1 viruses. NIBRG-14 was created by reverse genetics in the
manner described by Subbarao et al., [11] and is composed of the
NA and modified HA from A/Vietnam/1194/2004 and the
internal genes of A/Puerto Rico/8/34 (PR8), a high growing
laboratory adapted influenza A(H1N1) strain. Full length plasmid
clones of A/Vietnam/1194/2004 HA and NA genome segments
had to be generated with no prior knowledge of the precise
sequence of the NCRs; instead primers used were based upon
consensus sequences of H5N1 HAs and NAs available in public
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least one H5N1 virus [10]. In this study, the NCRs of the HA
genome segment of wild type A/Vietnam/1194/2004 were
determined and compared with those of NIBRG-14 and of other
highly pathogenic H5N1 viruses from public databases. From
these analyses viruses with modified NCRs were created, and the
effects of these modifications on virus growth and HA content,
important attributes of CVVs, were assessed.
Materials and Methods
Modified HA Plasmids
A/Vietnam/1194/2004 HA genome segments with modifica-
tions in their 39 NCR were generated by PCR using primers
designed to introduce the desired sequence changes. All primers
had SapI restriction sites at their 59 ends. The amplified genome
segments were inserted into pPST (a reverse genetics RNA
transcription vector) using SapI restriction enzyme sites and
standard cloning protocols [10]. All modified HA genes were
based on the HA genome segment of NIBRG-14 which contains
a deletion of the multibasic cleavage site.
Viruses and Cells
NIBRG-14 and NIBRG-65, derived by reverse genetics, have
been described previously [10,12]. The other H5N1 viruses used
in this study were also generated by reverse genetics using
modified HA segments containing point mutations in the 39 vRNA
NCR, the NA from A/Vietnam/1194/2004 and six genes from
PR8. Viruses were characterised by sequencing of their HA and
NA genes.
MDCK cells had been donated by the Common Cold Unit,
Salisbury, in 1982 and were maintained in Eagle’s MEM +10%
FBS [13].
RNA Lligation
For determination of the sequence of the NCRs of the HA RNA
genome segment, viral RNA was circularised by RNA ligation [7–
8]. Viral RNA was extracted from 200 ml of infectious allantoic
fluid in 1 ml Trizol containing 2 ml glycogen (50 mg/ml) and
incubated at room temperature for 5 min. After centrifugation in
a bench top centrifuge (13,000 rpm, 10 min, 4uC) the top layer
was removed and added to 500 ml propanol and incubated at
room temperature for 10 min. RNA was then pelleted in a bench
top centrifuge (13,000 rpm, 15 min, 4uC), washed in 70% ethanol,
air dried and resuspended in 20 ml water. The 59 end of the RNA
was dephosphorylated by adding 5 ml RNA to 0.5 ml of tobacco
acid pyrophosphatase (TAP), 1 ml 10X TAP buffer, 2 ml Madin-
Darby Canine Kidney (MDCK) cellular RNA and water to a total
volume of 10 ml. This was incubated for 1 hr at 37uC and the
enzyme was denatured for 5 min at 95uC. RNA was re-purified
using Trizol as described above, and resuspended in 20 ml water.
RNA ligation was performed with a 7 ml aliquot of de-
phosphorylated RNA added to 1 ml T4 RNA ligase, 1 ml
10 mM ATP and 1 ml1 0 6T4 RNA ligase buffer, incubated for
1h ra t3 7 uC, and the enzyme was denatured for 5 min at 95uC.
cDNA synthesis across the junction of the ligated HA RNA was
performed using 4.7 ml ligated RNA, 0.5 ml Superscript II reverse
transcriptase (100 U), 1.5 ml 100 mM DTT, 1.5 ml primer
(3.2 pM), 3 ml5 6dNTP, 3 ml5 6Superscript II buffer and water
to a total volume of 15 ml. The RT reaction was incubated for 1 hr
at 42uC and enzyme denatured for 5 min at 95uC. PCR was then
performed to amplify a DNA fragment spanning the junction of
the ligated RNA and reactions were purified. The PCR products
were sequenced to determine the sequence of the NCRs. The
MDCK RNA used in the 59 RNA dephosphorylation step was
extracted from 75 cm
2 flasks of MDCK cells that were trypsinised
and pelleted at 2,000 rpm for 5 min. The pellet was then treated
with Trizol and glycogen as described above using the same
incubation and centrifugation steps and RNA was resuspended in
Figure 1. NCR sequences of primers, plasmids and viruses in this study. The primers used to clone A/Vietnam/1194/2004 haemagglutinin,
the HA genome segment contained in the reverse genetics plasmid used to make NIBRG-14, RNA segment 4 (HA) of NIBRG-14 and of viruses
generated or used in this study are shown schematically. Sequences are shown in positive sense for the plasmid and 39 primer, and in negative sense
for vRNAs. Terminal sequences of the 39 and 59ends of the HA vRNA for NIBRG-14, A/Vietnam/1194/2004 (VN/1194), NIBRG-84, NIBRG-56, NIBRG-83
and NIBRG-65 were determined from viral RNA by RNA ligation. Sequences on beige background indicate sequences derived from the HA segment of
NIBRG-14, blue background represents sequences derived from PR8.
doi:10.1371/journal.pone.0036241.g001
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2 flask. The sequence of the complete HA
segment, including the non-coding regions, of wt A/Vietnam/
1194/2004 has been deposited in the GISAID database (accession
number EPI347615).
Virus Concentrates
Viruses were grown in the allantoic cavity of 11-day-old
embryonated hens’ eggs. Allantoic fluid was harvested 72 hours
post infection and clarified by centrifugation (4,000 rpm, 30
minutes, 4uC, Beckman JS 5.3 rotor). A second clarification was
performed (10,000 rpm, 30 minutes, 4uC, Beckman SW28 rotor)
and virus was pelleted from clarified fluid by centrifugation
(19,000 rpm, 90 minutes, 4uC, Beckman T19 rotor). Virus pellets
were resuspended in 10 ml PBS and loaded over 10 ml 30%
sucrose in SW28 tubes. Virus was pelleted by centrifugation
(25,000 rpm for 90 min at 4uC, Beckman SW28 rotor) and
resuspended in 100–200 ml PBS.
Work with 11-day-old embryonated hens’ eggs was carried out
under a UK Home Office Project Licence and approved by the
NIBSC Ethical Review Committee.
SDS PAGE Analysis – Deglycosylation Using PNGaseF
Deglycosylation was achieved using PNGase F (New England
Biolabs) [14]. Aliquots of each virus concentrate (typically 1–3 ml,
determined empirically) were denatured according to manufac-
turer’s instructions in a total reaction volume of 10 ml and samples
incubated at 37uC overnight (approx. 16 hours) with 1 mlo f
PNGase F enzyme (neat or diluted 1/10 or 1/100) in the buffer
provided by the manufacturer and 1% final concentration NP40
(provided with enzyme). Loading dye (2 ml) with 2% (v/v) b-
mercaptoethanol as reducing agent was added to each sample.
Samples were heated to 95uC for 3 minutes prior to loading onto
NuPage
TM precast 10% Bis-Tris gels and run at 125 V for 2 h
using MOPS buffer (Invitrogen) followed by staining using
Colloidal Blue (Invitrogen). Quantitation was carried out using
a Licor Image Scanner and ImageQuant software. The content of
HA for each sample was calculated as follows: firstly, the total viral
protein in arbitrary units was calculated by summing the values for
the HA1, HA2, NP and M bands and the HA1 and HA2 values
were summed to give the HA value. The amount of HA as
a percentage of total viral protein was calculated by dividing the
total HA by the total viral protein, multiplied by 100.
Growth Characteristics
Viruses at passage level VE2 (transfection in Vero cells and egg
passage 6 2) were diluted to 10
24,1 0
25 and 10
26 in PBS and
100 ml aliquots of each dilution were inoculated into 10–11 day
old embryonated hens’ eggs using 5 eggs per virus per dilution.
Figure 2. Sequencing of HA segment NCRs. Viral RNA was ligated and subjected to RT-PCR amplification as described in Materials and Methods
and the sequence of the resulting RT-PCR products was determined by dideoxynucleotide sequencing. Sequencing traces covering the 39 and 59
vRNA NCRs are shown. Vertical lines indicate positions 14–17, counted from the 39 end.
doi:10.1371/journal.pone.0036241.g002
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each egg assessed by haemagglutination assay following standard
protocols and using 0.7% turkey erythrocytes in PBS.
For each virus, a sample of highest titre allantoic fluid from the
growth experiment described above was analysed by plaque assay
on MDCK cells. Samples were diluted 10
24,1 0
25 and 10
26 in
PBS and 200 ml of each dilution was used to infect wells of a six
well plate, seeded with MDCK cells. Plates were incubated at
room temperature for 40 minutes to allow virus absorption. Plates
were overlaid with a media/Avicel suspension (16 MEM, 0.2%
BA, 16 L-glutamine, 0.01% Dextran, 0.0001% TPCK Trypsin,
0.18% Sodium Bicarbonate, 1.2% Avicel type RC-581) and
incubated for 48–72 hours at 35uC with 5% CO2 after which time
the overlay was removed and cells were fixed with 3%
formaldehyde solution. Cells were stained with naphthalene black.
For the growth kinetics experiment, embryonated eggs were
infected with a 10
25 dilution of each virus stock and incubated at
35uC for 12, 24, 36, 48 and 72 hours (five eggs per time point and
virus). Titres were determined using the haemagglutination assay
as described above and are shown as median HA titres.
Statistical Analysis
Statistical analysis was performed on raw data using Minitab 15
statistical software. Analysis of variance (ANOVA) was performed
using a general linear model with the Tukey method for pair-wise
comparisons [15].
Results
Comparison of NIBRG-14 HA and A/Vietnam/1194/2004
39NCRs
For the rapid development of an H5N1 candidate vaccine virus
in 2004, the modified HA and the NA genome segments of A/
Vietnam/1194/2004 had to be cloned into a reverse genetics
plasmid with no prior knowledge of their true NCR sequences.
Thus, primers were used in PCR that had been used successfully to
clone the HA genome segment of A/Hong Kong/213/2003 [10].
These primers were based on a consensus of publicly available (at
that time) HA NCR sequences of highly pathogenic H5N1 viruses.
The HA and NA plasmids derived from A/Vietnam/1194/2004
were then used immediately to create the CVV NIBRG-14 by
reverse genetics prior to their sequence confirmation [10].
Subsequent sequence analysis showed that the HA plasmid clone
used for rescuing NIBRG-14 contained a single nucleotide change
at position 14 (C vs. G) of the 39NCR compared to the synthetic
primer sequence (Fig. 1). Furthermore, the sequence of the HA
39NCR of the rescued virus, NIBRG-14, subsequently determined
by the RNA ligation approach, was different again with a sub-
stitution G to A at position 14 compared to the plasmid DNA
sequence from which it was derived (Fig. 1).
We then determined the true sequences of the NCRs of the HA
gene of the wt virus A/Vietnam/1194/2004, in order to compare
them to the sequences present in its derivative NIBRG-14. The
sequence of the parental wt 39NCR was unique and differed at two
positions, 14 and 16, from that of NIBRG-14:
14CAAG
17 vs.
14AAGG
17, respectively (Fig. 1). The sequences of the 59NCRs of
both viruses were identical (Fig.2).
Generation of a Panel of NIBRG-14 39 NCR Variant viruses
Comparison of the NIBRG-14 HA 39NCR with H5 HA
39NCR sequences reported in publically accessible databases
showed that the NIBRG-14 sequence did not conform to the
majority of these. We therefore generated two variant NIBRG-14
viruses (NIBRG-56 and NIBRG-83) containing the two most
frequently occurring 39NCR sequences (
14CAGG
17 and
14CAUA
17, respectively) of highly pathogenic H5N1 viruses. We
also generated a third variant with an HA 39NCR which was
identical to that of wt A/Vietnam/1194/2004 (NIBRG-84;
14CAAG
17). The sequences of the 39NCRs of the HA RNA
segments of these four NIBRG-14 derived viruses were de-
termined by the RNA ligation approach and found to be
equivalent to the primers used during their generation (Figs 1
and 2).
HA Content of NIBRG-14 NCR Variant Viruses
It was reported previously by us and others that yields of viral
protein and HA antigen of NIBRG-14 were low compared to
other candidate vaccine viruses [14,16]. It was thus of interest to
investigate whether or not the sequence of the HA 39NCR
influences yield and growth properties of NIBRG-14. In addition
to the viruses described above containing up to three nucleotide
differences in the 39 NCR as compared to NIBRG-14 (NIBRG-56,
NIBRG-83, NIBRG-84), virus NIBRG-65 which contains the HA
open reading frame of NIBRG-14 flanked by the 39 and 59 NCRs
of the HA of PR8 as described previously, was included in this
analysis [12]. Virus concentrates of all viruses were prepared and
the relative HA content, i.e. the amount of HA as a proportion of
total viral protein, was assessed using SDS-PAGE analysis of
deglycosylated samples [14]. No significant differences between
the viruses were found in this analysis (Fig. 3).
Growth Characteristics of NIBRG-14 NCR Variant Viruses
A range of virus dilutions was used to inoculate embryonated
hens’ eggs and growth was assessed by haemagglutination assay
(Fig 4A). Using a general linear model (ANOVA), NIBRG-83 was
found to have a statistically lower haemagglutination assay titre
than NIBRG-14, NIBRG-56, NIBRG-65 and NIBRG-84
(P,0.0001). No other pair-wise comparisons were statistically
different.
The allantoic fluids harvested from this growth study were used
to determine infectivity titres (in pfu/ml) by plaque assay on
MDCK cells (Figure 4B). Using a general linear model (ANOVA),
statistical differences were found between some of the viruses. Both
Figure 3. Haemagglutinin content of NIBRG-14 and panel of
NIBRG-14 NCR variant viruses. Virus concentrates were analysed by
SDS-PAGE following deglycosylation as described in Materials and
Methods. Values are the mean of three independent virus concentrates,
each analysed in triplicate. Error bars denote two standard errors from
the mean and are calculated from the three means of the three
independent concentrate sets for each virus.
doi:10.1371/journal.pone.0036241.g003
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higher infectivity titres than NIBRG-56 (p=0.0259 and 0.0021,
respectively), NIBRG-65 (p=0.003 and 0.0002, respectively) and
NIBRG-83 (p,0.0001 when compared to both NIBRG-14 and
NIBRG-84), whilst NIBRG-56 was significantly higher than
NIBRG-83 (p=0.0369). Although these significant differences
were found, the level of variability observed between the viruses
was similar to the variability observed between experiments
(estimated standard deviations of 0.31 and 0.46 of a log re-
spectively). Furthermore, the estimated standard deviation be-
tween replicates was 0.32 of a log which is on a similar level to the
variability between viruses. The largest difference in means
between viruses was between NIBRG-83 and NIBRG-84, with
a difference of 0.81 of a log and a 95% confidence interval of 0.47
to 1.16.
To determine the kinetics of growth of these viruses, embryo-
nated eggs were infected and haemagglutination titres of allantoic
fluids were determined at 12, 24, 36, 48 and 72 hours post
infection (Fig. 5). The kinetics of virus growth differed between the
viruses with statistically significant differences observed at 36 h.p.i.
(NIBRG-56 and NIBRG-83 significantly different from NIBRG-
14) and 48 h.p.i. (NIBRG-83 significantly different from NIBRG-
14 and NIBRG-83); however, at 72 h.p.i. all viruses had attained
a similar final HA titre.
Overall, while the changes made to the 39 NCR of NIBRG-14
in some cases led to statistically significant differences, we
concluded that these differences were not sufficient biologically
to warrant further investigation. Interestingly, none of the 39 NCR
variant viruses generated in this study improved the growth of
NIBRG-14.
Discussion
Sequencing of the coding regions of influenza A virus genome
segments is technically straightforward whilst extra efforts are
required to deduce the sequence of the terminal NCRs.
Consequently, researchers who focus on the coding regions of
the influenza virus genome tend to ignore the NCRs despite them
containing important cis-acting signals that affect various stages of
the viral life cycle, such as replication, transcription and genome
packaging. Even when sequence information is available in the
public domain for the NCRs, it is often unclear whether or not
these terminal sequences are ‘genuine’, i.e. whether they are
derived from sequencing the viral RNA (or cDNA copies thereof),
or whether they are primer-derived artefacts that do not
necessarily reflect the sequence present in the virus itself.
The lack of available NCR sequences and the lack of
information regarding the derivation of NCR sequences when
they are presented, constitute a problem for the design of primers
used for the segment-specific amplification of novel influenza
viruses. Therefore, primers may be designed based on information
that is incorrect or inaccurate. In the case of the H5N1 CVV
Figure 4. Final titres of NIBRG-14 and the panel of NIBRG-14
NCR variant viruses. (A) Embryonated hens’ eggs were infected with
dilutions (10
24,1 0
25,1 0
26) of each virus (five eggs per dilution, three
independent experiments). Values are the log2 means of the 10
25
dilution haemagglutination titres based upon three independent
experiments. Error bars denote two standard errors from the mean
and are calculated from the three experimental means for each virus. (B)
Allantoic fluids from the dilution giving highest mean HA titres for each
virus from the experiment shown in (A) were used to determine
infectivity titres, as described in Materials and Methods. Values are the
means of the log10 pfu/ml for each virus based on the means of the 3
independent experiments. Error bars represent 2 standard errors from
the mean and are calculated from the three experimental means for
each virus.
doi:10.1371/journal.pone.0036241.g004
Figure 5. Growth kinetics of NIBRG-14 and the panel of NIBRG-
14 NCR variant viruses. Embryonated hens’ eggs were infected with
a1 0
25 dilution of each virus and incubated for various times. Titres at
each time point were determined using the haemagglutination assay as
described in Materials and Methods. Values are the log2 median HA
titres; error bars denote standard deviations.
doi:10.1371/journal.pone.0036241.g005
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available at the time the virus was generated through reverse
genetics technology.
While NIBRG-14 has been widely used, including for the
production of vaccine lots for clinical trials [17,18], it has long
been recognised that yields obtained from this virus are less than
optimal [14,16]. In this study, we investigated whether the use of
altered NCRs, particularly those reflective of the wt parental virus
or of other wt H5N1 viruses, improved growth and yield
properties of the CVV.
No significant differences were found between the viruses that
had specific defined variations in their 39NCR in terms of HA
content, a relevant marker for vaccine yield [12,19], and none of
the NIBRG-14 NCR variant viruses showed improved growth
compared to NIBRG-14. Conversely, while some viruses showed
somewhat reduced final infectivity titres and slightly delayed
growth kinetics, changes to the 39 NCR did not massively reduce
the growth potential of NIBRG-14 in embryonated chicken eggs.
These findings may serve to assure the influenza vaccine
community that generation of CVVs using best-guess NCR
sequences, based on sequence alignments, are likely to produce
robust viruses that need not be changed if it is subsequently found
that their NCR sequences differ from the respective wt parental
virus(es). However, it would be useful if influenza sequences
deposited in publically accessible databases contained clear
annotation as to which portions of sequence are truly virus-
derived and which are primer-derived, if any.
In conclusion, we have found that minor alterations of the
39NCR of an H5N1 CVV had minimal impact on its growth and
HA yield characteristics. Further studies will be required to
establish whether more dramatic sequence changes involving both
non-coding and coding regions, similar to those described recently
[12,19], may be beneficial for vaccine production of a wide variety
of haemagglutinin subtypes.
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